CD274 and cancer: The approved PD-1/PD-L1 medications (atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, and pembrolizumab) are being successfully used to enhance the survival of cancer patients in combination with chemotherapy and targeted drug delivery by inhibiting binding of PD-1 to PD-L1 and preventing escape of cancer cells from the immune system via the use of antibody-based drugs [120].